Details for New Drug Application (NDA): 204782
✉ Email this page to a colleague
NDA 204782 describes FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, which is a drug marketed by Perrigo R And D and is included in two NDAs. It is available from eighteen suppliers. Additional details are available on the FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE profile page.
The generic ingredient in FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE is calcium carbonate; famotidine; magnesium hydroxide. There are two hundred and eighty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the calcium carbonate; famotidine; magnesium hydroxide profile page.
The generic ingredient in FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE is calcium carbonate; famotidine; magnesium hydroxide. There are two hundred and eighty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the calcium carbonate; famotidine; magnesium hydroxide profile page.
Summary for 204782
| Tradename: | FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE |
| Applicant: | Perrigo R And D |
| Ingredient: | calcium carbonate; famotidine; magnesium hydroxide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | 800MG;10MG;165MG | ||||
| Approval Date: | Aug 29, 2016 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
